Description
SLU-PP-332 Capsules | ERRα/γ Agonist — Oral Exercise Mimetic
SLU-PP-332 is a potent, orally bioavailable agonist of estrogen-related receptors alpha and gamma (ERRα/γ), transcription factors that regulate mitochondrial biogenesis, fatty acid oxidation, and skeletal muscle endurance capacity. Preclinical data showed a ~70% increase in running endurance compared to untreated controls. This capsule format (200mg per capsule, 30 capsules) is optimised for research protocols requiring consistent oral exposure.
Mechanism of Action
- ERRα/γ agonism — activates estrogen-related receptor transcription factors that govern mitochondrial biogenesis genes
- PGC-1α co-activation — synergises with PGC-1α to upregulate oxidative phosphorylation and fatty acid oxidation pathways
- Slow-twitch fibre conversion — promotes Type I fibre gene expression in skeletal muscle models
- Metabolic reprogramming — shifts substrate utilisation toward fat oxidation, sparing glycogen reserves
Research Areas
SLU-PP-332 is studied in metabolic adaptation, exercise physiology, obesity research, and mitochondrial dysfunction models. Its oral bioavailability makes it particularly suited to chronic dosing protocols. Compare with AICAR (AMPK pathway) and MOTS-c (mitochondrial peptide) for complementary endurance research models.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.






Dr. T. Bhardwaj –
SLU-PP-332 capsules for oral ERR agonist research. Content >99% confirmed. Capsule content uniformity excellent. COA detailed. Oral bioavailability model showed detectable ERRα/γ transcriptional activity.
A. Svensson –
200mg SLU-PP-332 capsules — convenient for oral dosing research. Content confirmed. COA thorough. Our mitochondrial biogenesis model showed ERR pathway activation in the oral format.
L. Osei –
Good SLU-PP-332 capsules. Content >98.5%. Capsule uniformity within spec. COA comprehensive. Practical oral format for our ERR nuclear receptor research.